September, 2024
September 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Michael Klichinsky: Carisma Therapeutics received FDA Fast Track Designation for CT-0525
Jun 27, 2024, 12:32

Michael Klichinsky: Carisma Therapeutics received FDA Fast Track Designation for CT-0525

Michael Klichinsky, Co-Founder and Chief Scientific Officer at Carisma Therapeutics, shared on LinkedIn:

“We are excited to share that Carisma Therapeutics received FDA Fast Track Designation for CT-0525 for the treatment of advanced HER2-overexpressing solid tumors.

More information here.”

Source: Michael Klichinsky/LinkedIn